Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.

Now Viewing

EP: 1.Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP: 2.Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP: 4.Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

EP: 5.Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP: 6.Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

EP: 7.The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP: 8.Unmet Needs and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke

Use of focal therapy was shown to prolong the duration of active surveillance.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

Related Content

Advertisement

May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke

Use of focal therapy was shown to prolong the duration of active surveillance.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.